
|Videos|July 5, 2022
Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma
Author(s)Urology Times staff
“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.
Advertisement
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5











